PA-PGW-AUTO-GLASS
PGW Auto Glass, LLC announced today that it has acquired PH Vitres d’Autos and affiliates from Driven Brands. PH Vitres d’Autos is a leading provider of wholesale auto glass distribution, retail installation, calibration and related services in eastern Canada. Based in Sainte-Perpetue, Quebec, PH Vitres employs more than 300 associates at 22 locations across Quebec, Ontario, New Brunswick and Nova Scotia.
“PH Vitres has a long history of operational excellence and outstanding customer service, and this acquisition enhances every element of our business,” said Todd Fencak, CEO of PGW Auto Glass. “PH Vitres will become part of our best-in-class footprint, and our teams will work together to ensure that our customers have the best solutions to run their businesses, including Everything Autoglass (www.everythingautoglass.com), a technology platform that allows customers to run all aspects of their day-to-day operations with features such as VIN decoding, route scheduling, inventory management, ADAS support and so much more.”
Mr. Fencak went on to say, “It is my pleasure to welcome the PH Vitres team to join us on our mission to be North America’s number one supplier of solutions to the auto glass industry.”
About PGW Auto Glass
PGW Auto Glass (www.pgwautoglass.com) is a leading distributor of automotive replacement glass, specialty parts, shop accessories and business technology solutions in North America, with more than 150 distribution branches throughout the U.S. and Canada. Offering same-day and overnight deliveries, PGW Auto Glass serves OEM dealerships, collision repair shops and automotive glass installers. PGW Auto Glass also provides a cost-effective, comprehensive business technology solution, Everything Autoglass, with a suite of features designed to help retail glass installers succeed (www.everythingautoglass.com). PGW Auto Glass is a portfolio company of One Equity Partners, a leading middle market private equity firm with approximately $10 billion in assets under management focused on transformative combinations within the industrial, healthcare and technology sectors in North America and Europe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240902323045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leading the Next Generation of Delicious, Natural and Nutritious Food: Upfield Renamed as Flora Food Group17.9.2024 16:00:00 CEST | Press release
Upfield Group B.V., global branded food champion, announces today that it has changed its name to Flora Food Group B.V. The name change is a substantial step in the company's evolution and follows a performance-driven transformation on multiple levels across the entire company. The new name reflects Flora Food Group’s evolved purpose of delivering the next generation of delicious, natural, and nutritious food that is more affordable and more sustainable than its dairy equivalents. Capitalizing on four global megatrends (population growth, demand for dairy-alternative solutions, animal welfare concerns, and environmental regulations), Flora Food Group leads the change with products that address these trends across four growing categories - butter and spreads, creams, liquids, and cheese - offering consumers a compelling choice. Leveraging its 150+ years of heritage and in-depth R&D expertise, Flora Food Group will seek to drive further conversion in butter, creams, liquids, and cheese,
Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex17.9.2024 15:04:00 CEST | Press release
Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma’s inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to customary purchase price adjustments, and potential deferred payments of up to GBP 148 million. The transaction is subject to customary closing conditions, including regulatory approval. “In line with our ambitions, Vectura has enabled us to develop a proprietary pipeline of inhaled therapeutics, and we remain committed to driving innovation in this space over the long-term,” said Jacek Olczak, PMI Chief Executive Officer. PMI’s 2021 acquisition of Vectura has been instrumental in kick-starting Vectura Fertin Pharma’s developmen
Koch Ag & Energy Solutions Selects Cognite to Create Transformative Change in Operations Through Data Discovery & Contextualization17.9.2024 15:00:00 CEST | Press release
Cognite’s Industrial Data Platform Cognite Data Fusion® to serve as a data modeling accelerator using Generative AI to scale across all assets Cognite, the Data and AI authority for industry, and Koch Ag & Energy Solutions (KAES), a global provider of solutions for the agriculture, energy, and chemical markets, today announced a collaboration focusing on leveraging Cognite Data Fusion® to accelerate their digital transformation journey. This collaboration will result in agile data-driven execution in maintenance strategy, turnaround execution, and general efficiency gains across all plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823846729/en/ Together, KAES and Cognite will deploy Cognite Data Fusion and co-innovate on custom, Generative AI solutions to accelerate KAES’s data journey, creating new ways of work in operations. Cognite Data Fusion will provide one foundation for operational data, which will be contex
Percona Redefines Cloud-Native Database Management with Percona Everest: the World's First Open Source Public DBaaS Alternative17.9.2024 15:00:00 CEST | Press release
Now generally available, the open source cloud-native database platform enables automated provisioning and management of multiple databases across environments, all within a single, intuitive user interface Percona, a global leader in enterprise-grade open source database software and services, today announced that its groundbreaking new database platform, Percona Everest, is now generally available to the public. Percona Everest is an open source, cloud-native database platform designed to deliver similar core capabilities and conveniences provided by database-as-a-service (DBaaS) offerings but without the burden of vendor lock-in and associated challenges. Percona Everest facilitates the work of developers, QA engineers, DevOps engineers, database administrators, and anyone who could benefit from self-serve deployment and management of MySQL, PostgreSQL and MongoDB on Kubernetes. Percona Everest simplifies database management and enables database deployment standardization across mul
Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’17.9.2024 14:00:00 CEST | Press release
Orbis’ platform first to systematically explore the macrocycle chemical space Collaboration will unite Vivtex’s best-in-class oral bioavailability screening with Orbis’ leading platform for the discovery and development of oral macrocycles Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the development of oral biologic therapies for major diseases. The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS™ platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs it calls ‘nCycles’. “This collaboration extends our ability to design for oral bioavailability into later stages of preclinical development with Vivtex’s extensively validated ex vivo porcine gut model, which is highly informative for human gut interactions. Our goal is faster development of the highest qualit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom